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Abstract
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has become a matter of concern worldwide, in particular
in the USA. For the analysis of emergence and spread, clear deﬁnitions based on epidemiological origin are needed for discrimination
between CA-MRSA, healthcare-associated community MRSA, and healthcare-associated MRSA (HA-MRSA). Although its role in patho-
genesis is currently under debate, the capability for Panton–Valentine leukocidin formation is associated with the majority of CA-MRSA
isolates from North America and from Europe. Most CA-MRSA isolates are attributed to clonal lineages different from HA-MRSA;
there are, however, clonal lineages from which both HA-MRSA and CA-MRSA have been reported (e.g. ST1, ST5, ST8, and ST22);
CA-MRSA ST8 (USA300), which is most frequent in the USA, has meanwhile been reported from Europe. CA-MRSA ST80 is widely
disseminated in Europe; because of its pronounced oxacillin heteroresistance phenotype, cefoxitin-based assays are advisable for reliable
detection. So far, CA-MRSA infections seem to be much less frequent in Europe than in the USA, where patients with particular pre-
dispositions and low social status are at especial risk.
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Introduction
Nosocomial infections caused by Staphylococcus aureus repre-
sent a considerable burden on healthcare; infected patients
have prolonged hospital stays, entail high hospital costs, and
suffer increased in-hospital mortality. With a few exceptions,
methicillin-resistant S. aureus (MRSA) has been a problem in
hospitalized patients for decades in many parts of the world
[1]. Historically, patients who developed MRSA infections in
the community had traditional risk factors associated with
treatment in nosocomial settings [2,3]. With the recent
emergence of MRSA infections in patients lacking contact
with a hospital setting or with humans treated in hospitals,
the term community-associated MRSA (CA-MRSA) has been
introduced [3–5]. CA-MRSA was ﬁrst reported from infec-
tions in remote populations in Australia, and in the USA, by
the end of the 1990s, cases of fatal infections in children in
Minnesota and North Dakota were the focus of attention
[5–7]. Since then, MRSA infections have also been reported
from Europe [8–13], from the near East, and from Asia and
Oceania [14]. Particularly in the USA, CA-MRSA strains are
pervasive among S. aureus isolates from skin and soft tissue
infections (SSTIs) [15–18]. Although much less frequent than
infections of the skin, CA-MRSA strains also can cause inva-
sive, rapidly progressive, life-threatening infections, such as
necrotizing pneumonia [18], severe sepsis [19], and necrotiz-
ing fasciitis [20]. Of particular concern are recent reports
about the introduction of highly epidemic CA-MRSA strains
into hospitals, followed by severe infections in hospitalized
patients [19,21]. When dealing with CA-MRSA strains, the
following questions need to be answered.
Are Clear Deﬁnitions Used for
Discrimination of CA-MRSA?
Usually, patients affected by CA-MRSA infections lack the
risk factors that are more commonly associated with the
acquisition of healthcare-associated MRSA (HA-MRSA).
These factors include prolonged hospital stay, care in
intensive-care units, prolonged antibiotic treatment, surgical
interventions, and close contact with MRSA-positive
individuals.
For patients with MRSA infection/colonization in the com-
munity but with previous hospitalization, residing in a nursing
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home, receiving home nursing or attending centres for dialy-
sis and/or centres for diabetes who acquire MRSA of hospital
origin [22], the term healthcare-associated community MRSA
should be used.
Furthermore, the emergence and spread of MRSA among
animals such as pets and horses has been observed [23–25].
Increasing reports on the wide spread of one particular clo-
nal complex (CC398) among commercial livestock (livestock-
associated MRSA) are of particular interest [26–28].
The epidemiological deﬁnition of CA-MRSA suggested by
Salgado et al. [3], and also advocated by the CDC [4], is shown
in Fig. 1. This epidemiological deﬁnition seems to be sensible
at ﬁrst sight. However, several more recent studies in the
USA have described a more complex epidemiology; both HA-
MRSA and CA-MRSA now circulate in the community, and
strains exhibiting molecular traits of previously clearly commu-
nity-associated MRSA (e.g. CA-MRSA ‘USA300’) are increas-
ingly being reported from nosocomial infections [21,29–34].
In addition to epidemiological criteria, antibiotic suscepti-
bility patterns and molecular typing have been thought to
distinguish CA-MRSA from HA-MRSA. Although CA-MRSA
isolates often remain more susceptible overall to erythromy-
cin, clindamycin, and ﬂuoroquinolones, we have to remember
that there are HA-MRSA isolates that still have a narrow
spectrum of resistance, such as ST45 in Europe [35], and
CA-MRSA isolates with resistance to oxytetracycline and to
fusidic acid, such as CA-MRSA ST80, and to macrolides and
ﬂuoroquinolones, such as CA-MRSA USA300 [36].
Regarding molecular typing characteristics, there are
CA-MRSA isolates attributed to clonal lineages for which
HA-MRSA isolates have not been reported so far, such as
ST59 and ST152; there are, however, also clonal lineages from
which both HA-MRSA and CA-MRSA isolates have evolved,
such as ST1, ST5 [10,12], ST8 [36], and ST22 [37]. The use of
staphylococcal cassette chromosome mec (SCCmec) IV as a
marker for CA-MRSA has substantial limitations, as SCCme-
c IV elements are also present in a number of HA-MRSA
lineages, such as ST5, ST254, ST22, and ST45 [38].
Epidemiological and clinical data provide strong evidence
for a close association between epidemic CA-MRSA and the
capacity for Panton–Valentine leukocidin (PVL) formation in
isolates from North America and from Europe [39]. Interest-
ingly, particular lineages of CA-MRSA that are widely dissem-
inated in Japan and Hong Kong lack PVL [40,41]. Although
the role of PVL in the pathogenesis of deep-seated SSTIs,
sepsis, and necrotizing pneumonia is far from being under-
stood, and other factors are probably also important, the
PVL-encoding genes lukS-PV and lukF-PV can be used as
markers for epidemic and CA-MRSA strains with comparably
high virulence.
Is Diagnosis in Clinical Bacteriology
Sufﬁciently Sensitive for Detection of
MRSA with Low-Level Oxacillin Resistance?
Reliable detection of methicillin resistance is particularly
problematic in MRSA isolates with pronounced heteroge-
neous expression of this resistance trait, such as isolates of
HA-MRSA ST45 [42] and CA-MRSA ST80 [43], which repre-
sents the most widely disseminated CA-MRSA lineage in
Europe.
When the disk diffusion assay is performed, the use of
5-lg disks and a semi-conﬂuent inoculum is problematic
MRSA in commercial
livestock (laMRSA), in petsMRSA
MRSA in the communityNosocomial MRSA
and in horses
(haMRSA)
hcaMRSA,
patients with risk factor
caMRSA,
patients without risk factor
Prolonged hospital stay
Care in ICU‘s
Prolonged antibiotic treatment
Surgical interventions
Close contact with MRSA- 
positive individuals
FIG. 1. Use of clear deﬁnitions: grouping
of methicillin-resistant Staphylococcus aureus
(MRSA) according to epidemiological origin.
CA-MRSA, community-associated MRSA; HAC-
MRSA, healthcare-associated community-onset
MRSA; HA-MRSA, healthcare-associated MRSA;
ICU, intensive-care unit; LA-MRSA, livestock-
associated MRSA.
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[43], and the results need to be conﬁrmed, as recommended
by the CLSI [44]. This problem can be overcome by the use
of cefoxitin as test substance [45]; here, attention needs to
be given to the type of agar medium used (Mueller–Hinton
Agar or IsoSensitest) when breakpoints and zone diameters
are being interpreted [46].
How Frequent are Infections Caused by
CA-MRSA in Europe?
In the USA, the emergence of CA-MRSA began with infec-
tions unrelated to hospitals in otherwise healthy individuals,
at ﬁrst in children [5,47], and later in professional players of
American football and other sports [48], military teams
[49,50], Alaskan natives [51], men who have sex with men
[18,52], drug abusers, and prisoners [53], for whom real out-
breaks have been described. During the past 5 years, how-
ever, CA-MRSA has obviously become more widely
disseminated.
Fridkin et al. [15], who examined 1647 cases of CA-MRSA
infection in two large metropolitan areas of the USA, reported
an 8–20% frequency of CA-MRSA among non-hospital-related
S. aureus infections. This is an agreement with more recent
data from Pennsylvania. In Los Angeles, the prevalence of
CA-MRSA increased from 29% in 2001 to 64% in 2004 [54];
similar data were reported from San Francisco in 2005 [55],
Sylmar in California [56], Georgia [57], and Texas [16].
In Europe, the emergence of CA-MRSA has been a focus
of attention since 2003; however, retrospective analyses indi-
cate sporadic cases occurring earlier. Of particular interest is
a series of infections with CA-MRSA ST80 in Denmark
encompassing 46 individuals in 26 households from Novem-
ber 1997 until June 2003 [58]. The prevalence is obviously
still considerably lower than that in the USA, although
increasing frequencies are being reported from countries
where the incidence of HA-MRSA is quite low, and thus CA-
MRSA is more the focus of attention, such as The Nether-
lands and Denmark.
In a study in Germany on 235 dermatology outpatients
from the Rhine/Main area attending the ambulatory depart-
ment of Heidelberg University for treatment of an S. aureus
infection, four of nine MRSA isolates were found to be
PVL-positive [59]. These patients affected had no previous
treatment in the nosocomial setting, whereas for the remai-
ning ﬁve of them the acquisition of nosocomial HA-MRSA
(ST32 and ST22) due to chronic infections was likely. Alto-
gether, 207 (1.74%) of 12 350 MRSA isolates of various
origin sent the German National Reference Centre for typing
from 2003 to 2006 were found to be PVL-positive [60].
A study in France in 2003 and 2004 on 238 patients
admitted to an emergency department revealed that 93 of
them (39%) were positive for MRSA; for 84, at least one
hospital stay was documented for a 12-month period prior
to this study. PVL-positive MRSA isolates were found in
seven (2.9%) of the 93 patients [61]. Among 14 253 patients
admitted to Geneva hospital in Switzerland, CA-MRSA prev-
alence as deﬁned by epidemiological criteria was 0.9/
1.000 admissions. Five of the MRSA isolates were PVL-
positive [10]. Although it was still present at a low level
in comparison to the USA, an increasing frequency of
CA-MRSA during 2000–2006 was reported from England
[62]. Although there is also a recent report about a severe
infection with CA-MRSA USA300 from Italy [63], CA-MRSA
seems, so far, to be rare in this country [64].
In Denmark, where the prevalence of MRSA is low in
general, CA-MRSA ST80 predominates among CA-MRSA
isolates belonging to other clonal lineages; epidemiological
analysis has indicated that the ST80 isolates have been
introduced to Denmark on multiple occasions from the
Mediterranean and the Middle East [65].
What Makes the Difference between the
USA and Europe?
The difference between the USA and Europe is clearly not a
question of different clonal lineages of CA-MRSA; strain
USA300, which is most frequent in the USA, has been pres-
ent in Europe for at least 2 years [60–63,66]. The ﬁndings of
several studies in the USA indicate that low social standards,
with homelessness in the worst case [55,56,67], are, besides
professional or leisure sports activities and military service,
the main risk factors for the emergence and spread of CA-
MRSA. This is very probably associated with elevated rates
of crime and incarceration. The spread of CA-MRSA in pris-
ons in the USA is well documented, and prior incarceration
has been identiﬁed as a risk factor [53]. Intravenous drug
abuse falls into the same category. Furthermore, sexual activ-
ities have to be considered, among heterosexuals [68] as
well as among men who have sex with men [52]. Thus,
human immunodeﬁciency virus infection and other sexually
transmitted infections, such as syphilis and/or group B strep-
tococcal infection/colonization, which indicate a high level of
promiscuity, have been more frequently found among individ-
uals with CA-MRSA infections in the USA [69].
CA-MRSA can spread rapidly if purulent skin lesions are
not treated in an appropriate manner, owing to a lack of
sufﬁcient access to healthcare. All of these factors may be
present in particular large urban communities in the USA
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[70]. There are very probably similar communities in some
larger European cities; with respect to infectious diseases, the
situation in large Russian cities has to be mentioned. Under
these circumstances, we cannot exclude the possibility of a
spread of CA-MRSA similar to that in the USA.
Widespread Dissemination of Particular
Clonal Lineages or Frequent de novo
Evolution of CA-MRSA?
An essential prerequisite for answering this question is
molecular typing. For nearly three decades, phage typing was
broadly used in S. aureus epidemiology, and became increas-
ingly difﬁcult to interpret in the case of tracing and discrimi-
nation of MRSA. By the early 1990s, SmaI macrorestriction
(pulsed-ﬁeld gel electrophoresis) had been introduced, and
this method represents the current reference standard with
respect to discriminatory power [71]. Clusters of SmaI pat-
terns are widely congruent with clonal lineages as deﬁned by
multilocus sequence typing (MLST) [72], which is based on
allelic polymorphisms of seven housekeeping genes [73].
MLST lineages widely reﬂect the evolution of the population
structure of S. aureus [38]. Spa-sequence typing, which is
based on the repeat polymorphism of the X-region of the
spa gene, is nearly as discriminatory as SmaI macrorestriction
patterns [74]. When spa types are grouped by use of the
BURP algorithm [75], these clusters are fairly congruent with
clonal complexes as obtained from BURST analysis of MLST
ﬁndings [72]. There are a few exceptions in the case of
recombinational exchange of large chromosomal regions
containing the spa gene (e.g. in HA-MRSA ST239) [76].
When, however, spa types of particular CA-MRSA clonal
lineages are attributed to clonal lineages by means of the
BURP algorithm, different clonal lineages can be grouped
together, such as CA-MRSA ST80 with CA-MRSA ST1,
methicillin-resistant S. aureus (MSSA) ST15, MSSA ST097 and
MSSA ST07, and CA-MRSA ST30 with MRSA ST398 [77].
PCRs for arcA (ST8), seh (ST1) and etd (ST80) are helpful
for unambiguous attribution of the most frequent CA-MRSA
isolates to clonal lineages, and can be performed in routine
clinical bacteriology laboratories [78].
The most frequent spa types among CA-MRSA are shown
in Table 1, and the clonal lineages from which HA-MRSA and
CA-MRSA have evolved are shown in Fig. 2.
CA-MRSA strains may have evolved: (i) from already
existing PVL-positive MSSA by acquisition of SCCmec ele-
ments; (ii) from HA-MRSA by acquiring further genes,
enabling them to cause invasive SSTIs and to spread more
efﬁciently outside the hospital (e.g. lukS-PV/lukF-PV-contain-
ing phage); or (iii) by acquisition of SCCmec and other genes
from so far ‘innocent’ MSSA clonal lineages.
Examples of (i) are obviously CA-MRSA ST30 (USA400)
[79]; MLST and spa sequence typing suggest possibility
(ii) for CA-MRSA ST5 and ST22, although a more detailed
genome-wide analysis of single-nucleotide polymorphisms
indicates convergent evolution [80]; and examples of (iii) are
CA-MRSA ST1, ST8, ST59, ST80, and ST152.
What Can We Learn from Genomics?
At present, the genomes of 11 MRSA and MSSA clinical
strains, of both community and hospital origin, and those of
two bovine strains, have been deposited in the GenBank
database. Of particular interest with respect to evolution
and features characteristic of CA-MRSA are comparisons
of the genomes of CA-MRSA and HA-MRSA of the same
clonal lineage, as well as with their most probable MSSA
ancestor.
At present, high-throughput sequencing technologies are
becoming increasingly available, and will make essential
TABLE 1. Typing characteristics and geographical dissemination of community-associated methicillin-resistant Staphylococcus
aureus
MLST, ST spa types SCCmec Further markers Resistance phenotypes Geographical dissemination
1 t175, t1383 IVa seh OXA USA, sporadic in several European countries
5 t002 IV OXA, GEN The Netherlands, Switzerland, Germany, Slovenia
8 t008 IVc arcA, msrA, mphB OXA, ERY, CIP, MFL USA, Europe, Asia
22 t310 IVa, IVh OXA, ERY, CLI, CIP, MFL Scotland, Germany
30 t021 t019 Iva OXA Oceania, USA, Baltic area, Denmark, UK, sporadic in
other European countries
59 IV OXA Europe, Asia, North America
80 t044, t131, t343 IVh etd OXA, TET, FUS, KAN, (CIP) All Europe, North Africa
152 t355, t1123 V OXA, GEN Slovenia, Kosovo
arcA, arginine deiminase; etd, exfoliative toxin D; mphB, macrolide phosphotransferase B; msrA, macrolide efﬂux; seh, staphylococcal enterotoxin; CIP, ciproﬂoxacin; CLI, clin-
damycin; ERY, erythromycin; FUS, fusidic acid; GEN, gentamicin; KAN, kanamycin; OXA, oxacillin; MFL, moxiﬂoxacin; TET, tetracycline; MLST, multilocus sequence typing;
ST, sequence type.
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contributions to the elucidation of evolutionary relations-
ships, as already performed for salmonellae [81].
Comparative whole genome sequencing of ten isolates from
the widely disseminated CA-MRSA USA300 clone revealed
very recent diversiﬁcation rather than convergence [82].
The comparison of the genomes of CA-MRSA USA300
from the USA and of HA-MRSA COL from Europe, which
both belong to lineage ST8, revealed that there are no
pronounced differences in gene content besides the arginine
catabolic mobile elements (ACME) gene cluster on an
SCCmec element and lukS-PV/lukF-PV, which are both
present in CA-MRSA USA300. Likewise, comparison of
recently obtained clinical MRSA USA300 and MSSA isolates of
lineage ST8, both originating from Houston, Texas, revealed
only subtle genetic genomic differences, with respect to the
ACME cluster, the SCCmec element, a region containing
genes for a number of conserved hypothetical proteins, and
32 non-synonymons single-nucleotide polymorphisms [83].
The ACME gene cluster in CA-MRSA USA300 encodes
enzymes representing an additional arginine decomposition
pathway, with arginine deiminase (ArcA) as a key enzyme.
This might contribute to depletion of arginine as a source
for NO production by granulocytes, as well as to enhanced
colonization on epithelia by neutralizing lower-pH environ-
ments (ammonia production). There are recent data that
demonstrate a difference in survival of isogenic USA300
ACME-positive and ACME-negative derivatives in a rabbit
infection model [84].
Although lukS-PV/lukF-PV is a genetic marker for CA-
MRSA, the exact role of PVL in the pathogens, as suggested
by a study on necrotizing pneumonia [85], remains to be
shown in more detail. As shown in a recent study on gene
expression directly in human tissue, PVL, together with
other secreted toxins, has a high level of expression during
superﬁcial and invasive CA-MRSA infections [86].
As shown at least for CA-MRSA ST1 USA400, ST8
USA300, and ST59, strong expression of small, phenol-
soluble molecules (PSMs) is probably another important
characteristic of CA-MRSA. These peptides have a remark-
able ability to recruit, activate and subsequently lyse human
neutrophils, and their role in bacteraemia, as well as in SSTIs,
has been demonstrated just recently in murine models [87].
Are There Efﬁcient Methods for Infection
Control in Cases of CA-MRSA Infection?
As described above, risk factors for acquisition and transmis-
sion that conﬁrm the basic principle of transmission of S. aur-
eus by contact have been identiﬁed. A study in New York
has shown that nasal carriage of CA-MRSA among household
members of patients with CA-MRSA infections is much more
frequent than among the general population [88]; also, family
outbreaks of CA-MRSA infections have been reported [89].
Most of the risk factors described above do not apply to
young children, for whom CA-MRSA infections have also
been reported [90]. Starting from a few cutaneous infections
which were recognized too late or not sufﬁciently treated,
CA-MRSA can efﬁciently spread among groups of children
through play and sports activities.
Besides routine social interactions, CA-MRSA is obviously
transferred by physical interactions among athletes in com-
petitive sports [50], and exercises among military personnel
[91]. The acquisition and subsequent transmission of
CA-MRSA is facilitated when it comes into contact with
non-intact epithelium, and minor superﬁcial injuries of skin,
such as abrasions and lacerations, are more frequent among
the groups mentioned above.
Furthermore, transmission of CA-MRSA by sexual
contacts, both among men who have sex with men and
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FIG. 2. Probable genetic relatedness of
methicillin-resistant Staphylococcus aureus
(MRSA): simpliﬁed minimum tree spanning
tree based on multilocus sequence typing pro-
ﬁles (seven housekeeping genes). CA-MRSA,
community-associated MRSA; HA-MRSA,
healthcare-associated MRSA; SNP, single-
nucleotide polymorphism.
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among heterosexual individuals, has been reported. Besides
nasal colonization, colonization of the genital area can be
important as a potential CA-MRSA reservoir [68]. Transmis-
sion is also likely if infected individuals share personal items,
such as clothing, towels, razors, and sports equipment.
For these reasons, improvement of personal hygiene is an
essential prerequisite for prevention. This includes hand
washing with soap and warm water, and the use of antibacte-
rial hand sanitizers and hand gels. Individuals in group facili-
ties should regularly shower with soap and warm water
when ﬁnishing their activities, and they should not share
items, as mentioned above.
Early detection of CA-MRSA by routine clinical examina-
tion is very important; therefore, bacteriological investigation
should be performed, along with surgical treatment (incision
and draining) of SSTIs.
Individuals affected by potentially cutaneous CA-MRSA
infections should avoid direct contact with non-colonized/
non-infected individuals in families, sport teams, schools, and
military facilities. Affected patients and family members
should be checked for nasal colonization with CA-MRSA,
and in case of positive results, sanitation should be per-
formed, preferentially by nasal application of mupirocin oint-
ment, in combination with chlorhexidine body wash.
When CA-MRSA SSTIs persist, worsen, and/or recur,
despite appropriate surgical intervention, additional systemic
antimicrobial therapy is necessary. CA-MRSA can be resis-
tant to other alternatives, such as doxycycline in the case of
ST80, to erythromycin (this includes potential resistance to
clindamycin when coded by erm genes), and to moxiﬂoxacin
in the case of ST8.
There remain a number of options for empirical oral ther-
apy with substances for which resistance is still infrequent or
absent in CA-MRSA and that reach sufﬁcient concentrations
in skin and in the secretions of the upper respiratory tract
[92,93]. Although successful co-trimoxazole treatment of CA-
MRSA SSTIs has been reported [51], one should keep in mind
that this antibacterial is only bacteriostatic in the case of
staphylococci. Other alternatives are new antistaphylococcal
agents such as linezolid, tigecycline, and daptomycin [93,94].
Furthermore, possible side effects and drug interactions
have to be considered, such as the contra-indication for rif-
ampicin in human immunodeﬁciency virus-infected patients
treated with proteinase inhibitors, and the development of
haematological or renal side effects resulting from the use of
co-trimoxazole.
The rather complex approach to the prevention and
treatment of SSTIs caused by S. aureus was found to be
successful in the case of an outbreak of furunculosis with
MSSA (clonal lineage ST121) in northern Germany in 2005
[95], and a decolonization programme was also found to be
efﬁcient in controlling the dissemination of CA-MRSA ST80
in Denmark [58].
Emergence of Livestock-Associated MRSA
in Humans in the Community
MRSA of clonal complex CC398 (eight MLST types, most
frequent spa types t011, t034, t108, t571, and t2974) is obvi-
ously widely disseminated among pigs in European countries
with high-density pig farming, such as The Netherlands [96],
Denmark [97], and Germany [98], but also in Canada and in
the USA [99]. Besides pigs, MRSA ST398 has also been iso-
lated from veal calves [100], horses [101,102], and dogs
[103]. Thus, animal association has also to be taken into con-
sideration in the epidemiological analysis of SSTIs with
MRSA. Further steps of adaptation to humans should be
carefully monitored, as suggested by the emergence of a
cluster of infections with PVL-positive MRSA ST398 in a
Chinese hospital [104].
Of particular interest is the question of dissemination to
humans exposed to MRSA-colonized animals, to their family
members, and then to the community. Nasal colonization of
exposed humans is frequent, and although it is less frequent,
there is obviously transmission to family members of farmers
[105]. Although rare in relation to PVL-positive CA-MRSA,
MRSA CC398 is able to cause severe SSTIs in humans who
need surgical intervention and, in some cases, even those
who need hospitalization [106–108].
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